In this review, we shall outline recent advances in our understanding of the movement disorders which geriatricians encounter in their clinical practice. Many of these diseases are no longer simply considered disorders of movement: carefully conducted longitudinal studies have shown that concomitant cognitive dysfunction, neuropsychiatric disturbance and behavioural issues are frequent and exert a heavy burden on the individual and their carers. Great progress has been made in understanding the molecular and cellular processes that drive the pathological changes in these conditions, as have advances in neuroimaging and preclinical drug discovery programmes. Unfortunately, this is yet to translate into disease-modifying therapies for these progressive disorders. Advances have been also made in non-pharmacological interventions such as tailored physiotherapy and speech therapy programmes. The important contribution of palliative care has been recognised and increasingly incorporated into the multidisciplinary approach. The UK is at the forefront of research into these conditions and geriatricians are well placed to contribute to research through recruiting patients to observational studies or therapeutic trials, particularly
Introduction
In this 'New Horizons' article, we will focus on the movement disorders which geriatricians encounter in routine clinical practice. We will outline recent advances in the clinic and laboratory and how these are translating into better understanding of the pathological processes driving these conditions, improved diagnostic accuracy and, ultimately, paving the way for the development of disease-modifying therapies.
Degenerative movement disorders
No longer considered purely disorders of movement, many patients will have co-existent cognitive impairments and neuropsychiatric disturbances which are equally troublesome for them and their carers. These degenerative proteinopathies, which are outlined in Table 1 , are characterised by abnormal protein handling and oxidative stress with subsequent cell toxicity and death. Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are synucleinopathies, whereas progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and some forms of frontotemporal lobe degeneration are driven by tau pathology. The clinical features are the manifestation of degeneration in select neuronal populations influenced by the distribution of pathology, the proteinopathy driving the disease and any co-existent pathological processes.
of PD is degeneration of the dopaminergic neurons within the substantia nigra pars compacta. Driven by the deposition of insoluble phosphorylated α-synuclein-containing inclusions within the neuronal cytoplasm as Lewy bodies, or axons as Lewy neurites, these lesions are found throughout the central and autonomic nervous systems and become more widespread with disease progression [2] . Animal and cellular models have confirmed that mitochondrial dysfunction, abnormal protein aggregation and oxidative stress are implicated in the pathogenesis of PD, but whether Lewy pathology is directly cytotoxic or represents a failed response by the cell to confine and eliminate cytotoxic proteins remains unclear [3] .
The incidence of PD increases with age [1] , and an older age at onset is strongly associated with faster disease progression [4] . Accounting for only a small proportion of all cases, monogenetic forms predominate in those with young-onset PD and at least eight loci of importance have been identified with Genome Wide Association Studies [5] . Within the general population, a positive family history may be an important risk factor and mutations in the leucine-rich repeat kinase 2 gene (designated PARK 8) are found in 1-2% of European patients with idiopathic PD [6] . Some mutations are associated with certain clinical features; the H1 haplotype of the microtubule-associated protein tau gene confers an increased risk of dementia [7] . The UK-wide 'Tracking Parkinson's' Study aims to recruit 2500 patients with new and young-onset PD to further define the importance of genetic factors in the development and progression of PD. Environmental factors such as solvents containing trichloroethylene [8] and pesticides [9] have been linked to PD and require further evaluation.
Clinical advances
The clinical features of PD encompass motor abnormalities, cognitive impairments, autonomic dysfunction and neuropsychiatric disturbances. Recent research has focused on motor phenotype classification and its correlation with pathology and patterns of disease progression. Four distinct clinical phenotypes have been described and are outlined in Table 1 . Each is associated with a different disease trajectory: those with younger onset or tremor-dominant presentations appear to have a longer time interval to developing falls and dementia [10] . Patients with postural instability and gait difficulty typically develop falls and dementia sooner [11] , however, these patients are often older and have more extensive cortical LB deposition [10] .
Non-motor symptoms (NMS) are important predictors of the quality of life [12] and approximately half of NMS are not reported or recorded [13] . Using the 30-point NMS screening questionnaire (NMSQuest) in 545 patients across all stages of PD, Martinez-Martin et al. [14] reported nocturia to be the most prevalent NMS. Cognitive, perceptual, autonomic, sleep and sexual symptoms occurred in over 30% of patients. A recent incidence study highlights that those with very early PD experienced a greater number of NMS when compared with age-matched controls, and those with the postural instability gait disorder subtype of the disease had a higher burden than those with tremordominant disease (Khoo et al., submitted). The importance of recognising and managing NMS is emphasised in the National Institute for Health and Clinical Excellence Guideline on PD [15] . Many NMS predate the onset of motor dysfunction by many years [16] , offering further insight into the development of PD and suggesting a 'premotor phase.' LBs have been found in the colonic mucosa of those with PD up to 5 years prior to the onset of motor parkinsonism [17] , possibly suggesting an intestinal route of entry with centripetal, or rostral spread. Constipation and disturbances of sleep, mood and olfaction are common and collectively may represent a Parkinson at Risk Syndrome, which is currently the subject of intense study, the ultimate goal being to identify those at highest risk of developing PD and allowing the rational targeting of future diseasemodifying strategies.
Cognitive and neuropsychiatric issues
Dementia may ultimately develop in almost 80% of those with PD [18] . and clinical purposes, DLB is differentiated from PDD by the '1-year rule' [19] : the diagnosis of DLB requires cognitive dysfunction to precede motor symptoms, or occur within 1year of motor onset. In contrast to the motor manifestations of PD, which reflect dopaminergic deficiency, dementia is underpinned by a profound cholinergic deficiency, even greater than that seen in AD [20] . A recent Cochrane Review supports the use of cholinesterase inhibitors, with rivastigmine having modest benefits in global function, cognition, behavioural symptoms and activities of daily living in those with PDD [21] . For those with early PDD, the Health Technology Assessment programme funded UK-based multi-centre MUSTARDD-PD trial will evaluate the effects of the early institution of donepezil and recruitment will begin shortly.
Subtle cognitive dysfunction or mild cognitive impairment (MCI) occurs in around a quarter of patients and is reported across all stages of PD [22] . PD-MCI is defined as a cognitive decline which, although, not normal for age, is still associated with essentially normal functional activities [22] and guidance for formal neuropsychological testing is available [23] . Single domain impairments occur more frequently than multiple domain impairments; attention and executive impairments are most commonly observed, in contrast to the general ageing population where amnestic deficits predominate [22] . Two longitudinal studies reported increased dementia risk in those with PD-MCI [7, 24] ; however, further information from large observational studies is needed to inform the prognostic significance of PD-MCI.
Across all stages of PD, major depression is reported in 5-20% of patients, with a further 1-30% suffering minor depressive episodes [25] . The evidence base for treatment is limited, with trials often small and of short duration. Selective serotonin reuptake inhibitors are commonly prescribed and a recent placebo-controlled double-blind randomised controlled trial (RCT) of venlafaxine and paroxetine supported the use of both over placebo [26] . There is some evidence supporting tricyclic anti-depressants such as nortriptyline and desipramine in PD depression [27, 28] , but their anti-cholinergic properties often make them unsuitable for this population. The anti-depressant properties of pramipexole have recently been recognised [29] .
Impulse control disorders (ICDs) in those receiving dopamine agonists (DAs) are an increasingly recognised phenomenon. In a cross-sectional study of over 3,000 patients with PD [30] , 13.6% of patients were identified as having an ICD, with 3.9% having two or more ICDs. Compulsive shopping was most prevalent (5.7%), followed by gambling (5.0%), binge-eating (4.3%) and compulsive sexual behaviours (3.5%). ICDs were more frequent in those prescribed a DA compared with other antiparkinsonian medications, although it should be noted that this study consisted of subjects aged under 75, and therefore the applicability to older patients may be limited. Predominately associated with DA use, ICDs have been reported in patients receiving levodopa [31] and following deep brain stimulation (DBS) [32] . Risk factors for the development of an ICD include male sex, younger age and a history of gambling or depression, and these should be sought prior to the initiation of DAs and behaviours suggestive of an ICD should be enquired about regularly.
New treatments for PD
In general, the drug development pipeline for PD is relatively sparse, and almost 50 years after their introduction, L-dopa preparations remain the most effective form of oral therapy. Stem cell and gene transfer strategies have thus far proved disappointing. There is a need for better treatments to address not only the dopaminergic deficits, but also the other neurotransmitter derangements that occur within the cholinergic, serotonergic and noradrenergic systems. Table 2 shows some of the drugs currently being trialled for PD in Europe and North America. Disease-modifying drugs that slow the rate of dopaminergic nigral degeneration would simplify the management of motor problems; likewise slowing the onset of dementia and non-motor features would significantly enhance the quality of life for the individual and their carer.
DBS of the subthalamic nucleus (STN) is an established surgical option [33] . Key to its success is careful lead placement and patient selection: Patients should be under 70 with L-dopa responsive disease and no significant neuropsychiatric or cognitive disturbance, which unfortunately excludes a significant proportion of the population seen by geriatricians. STN stimulation has little impact upon gait dysfunction, axial symptoms and falls. Undergoing profound degeneration in PD, the pedunculopontine nucleus (PPN) provides significant cholinergic input to the basal ganglia and cortex [34] and may play an important role in posture and gait. A recent double-blind RCT [35] of unilateral PPN stimulation demonstrated benefit in terms of reducing falls, but not the overall UPDRS score; for this to be achieved, bilateral stimulation of the PPN and subthalamic region may be required [36] .
Non-drug treatments
Trials of multidisciplinary rehabilitation and exercise are underway in the UK and Holland. Input from PD specialist nurses improves patients' sense of well-being at no additional cost [37] . Speech and language therapy in the assessment and management of dysphagia is well-established, for quiet speech and dysphonia the Lee Silverman Voice Treatment may be beneficial [38] . Evidence is growing for the role of physiotherapy, which may be beneficial in improving gait, freezing and falls, but it is important to note that different strategies are required for different disease stages and experienced physiotherapists are essential [39] . [19] . Pathologically, there is extensive cortical and neocortical LB deposition which correlates with the severity of cognitive decline [40] as well as basal forebrain cholinergic neuronal loss, neurofibrillary tangles and deposition of β-amyloid, the latter occurring more often in DLB than PDD. Differentiation from AD in its early stages can be challenging and 123I-FP-CIT SPECT imaging may be helpful [41] . Symptomatic treatment remains limited to rivastigmine [42] or donepezil, which improves both cognition and behavioural features [43] . Most recently memantine has been shown to improve some neuropsychiatric features [44] .
Dementia with Lewy bodies
Multiple system atrophy MSA manifests as severe autonomic dysfunction with cerebellar features (MSA-C), poorly levodopa-responsive parkinsonism (MSA-P) or both [45] . The pathological hallmark is the presence of α-synuclein containing glial cytoplasmic inclusions in the central nervous system (CNS) [46] . While most cases are sporadic, polymorphisms in the SNCA gene have been identified, adding to our understanding of the pathogenesis [47] . To date, no treatments have been shown to slow the disease progression or improve survival. Riluzole, which prolongs survival in motor neuron disease (MND), did not improve survival in MSA patients in the Neuroprotection and Natural History in Parkinson Plus Syndromes study [48] . A trial of rasagiline in patients with MSA-P is due to fully report later in 2012 but did not demonstrate efficacy. Potential disease-modifying therapies that have shown early promise in mice models include erythropoietin [49] and rifampicin [50] ; the later reduces α-synuclein fibril formation and a human trial is underway.
Tauopathies
Tauopathies are characterised by the accumulation of hyperphosphorylated tau protein within neurons and glial cells in the CNS. Normally, tau is a soluble microtubule-associated protein found within the neuron: in the disease state the abnormally insoluble tau forms fibrillar structures of aggregated, hyperphosphorylated and ubiquinated tau with subsequent cellular toxicity. The result is a range of heterogeneous clinical syndromes with varying degrees of parkinsonism and dementia-particularly with frontal lobe involvement or an MND-like appearance [51] .
Progressive supranuclear palsy
Progressive supranuclear palsy is the most common tauopathy and is characterised by abnormal deposition of fourrepeat tau fibrillary tangles in neurons and glial cells within the midbrain, pallidum, thalamus and STN [51] . The classic Steele-Richardson syndrome typically presents in patients over 40 years of age with akinetic rigidity, early falls (often backwards) and supranuclear vertical gaze palsy or slowing of saccades. Other features include frontalis muscle hyperactivity giving the patient a startled expression, and a deepened voice. Neuropsychiatric disturbances such as apathy, change in social behaviour and aggression are prominent. Early impairments of cognition manifest as reduced verbal fluency, inflexibility of thought and impaired ability to recognise emotions [52] . Dementia is almost universal with disease progression. In contrast to the synucleinopathies, hallucinations, autonomic dysfunction and sleep disturbance are rare. PSP is relentlessly progressive, with death occurring after a mean of 7 years. More recently, a PSP variant designated PSP-Parkinson (PSP-P) has been described with clinical features similar to PD: gaze palsy is less prominent; bradykinesia, rigidity and tremor are more unilateral and cognition is preserved for longer [53] , these patients may respond to L-dopa and the mean survival is longer. Pure akinesia with gait freezing is another uncommon phenotypic variant of PSP. Studies of cholinesterase inhibitors [54] , gabapentin [55] and riluzole [48] have been disappointing. Disease-modifying strategies are being developed, which aim to reduce tau deposition via inhibition of tau hyperphosphorylation and aggregation. Glycogen synthase kinase-3 (GSK-3) is critical for tau hyperphosphorylation, but trials of GSK-3-inhibiting drugs, including lithium and Tideglusib have been disappointing. A further approach is to stabilise the neuronal cytoskeleton through enhancing the synthesis of Activity-Dependent Neuroprotective Protein with nasal davenutide (Allon Therapeutics) and trials are underway at present. Coenzyme Q-10, which supports mitochondrial function, showed promise in a phase II trial and a further trial is ongoing. A phase III trial of rasagiline is currently recruiting participants.
Corticobasal degeneration
Diagnosis of CBD is challenging: it is rare, and has a variety of presentations. It may present with the classical features of corticobasal syndrome (CBS) including limb dystonia, unilateral limb apraxia, action myoclonus or cortical sensory loss; or with a more PSP-like variant with aphasia or behavioural change [56, 57] . CBS is a clinical phenotypic descriptor which may be the manifestation of a range of different pathologies including tau, Alzheimer's disease pathology, LBs or frontotemporal lobar degeneration [57] . Pathological four-repeat tau accumulation is common to the CBD and PSP and may be present in up to half of cases of CBS [57] . Treatment is supportive; rivastigmine may improve neuropsychiatric features but with no impact upon cognition [58] , and L-dopa is not helpful.
Other movement disorders
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disease caused by a cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the Huntington gene on chromosome 4 [59] with severe neuronal loss in the putamen and caudate. The disease shows anticipation and the age of onset correlates inversely with the number of trinucleotide repeats. The clinical features encompass chorea, dystonia, cognitive, neuropsychiatric and metabolic disturbances and may develop between the ages of 1 and 80 years. Current treatment strategies are unsatisfactory and include the use of antidepressants and antipsychotics. Trials of striatal foetal implants are underway, as are searches for neuroprotective treatments including coenzyme Q10. DBS has been used for disabling chorea in younger patients but experience is limited [60] . North American and European studies are ongoing in the search for reliable biomarkers for those with pre-manifest HD.
Essential tremor
Essential tremor has a prevalence of 0.4-0.9% across all age groups, rising to 4.6% in those over 65-year-old [61] . No longer labelled as 'benign,' the tremor often progresses and may be associated with neuropsychiatric, motor and functional co-morbidities [62] . Inherited in an autosomal dominant manner with reduced penetrance, no convincing loci have been identified despite exhaustive study, possibly due to considerable heterogeneity within the patient population and confounding factors such as age and co-morbid disease. Pathologically, there may be a loss of cerebellar Purkinje cells, particularly those expressing GABA A and GABA B receptors in the dentate nucleus of the cerebellum; brain stem LB deposition has being reported in some studies also [63] . Propanonlol is established as the first-line therapy, but up to half of patients fail to respond [64] . Gabapentin and topiramate are the second-line and may work via gamma-aminobutyric acid receptor activation. Refractory cases may be considered for DBS of the ventralis intermedius nucleus of the thalamus, often with good results.
Dystonic tremor
This diagnosis has emerged with the increased use of dopamine imaging in therapeutic trials where a misdiagnosis rate of up to 15% was noted after imaging [65] . Labelled as 'scans without evidence of dopaminergic deficit' (SWEDDS), many of these patients demonstrated mild dystonic posturing and were thus considered to have dystonic tremor. The tremor is usually an atypical jerky rest tremor that is generally unilateral, may be focal and may display a geste antagoniste (sensory trick that reduces tremor) [66] . Available oral treatments are unsatisfactory, but botulinum toxin injection to focal muscle groups has been tried with some success.
Horizon scanning
The UK is at the forefront of movement disorder research and geriatricians are well placed to participate in this. Within England, the topic-specific NIHR-Dementias & Neurodegenerative Diseases Research Network (NIHRDeNDRoN) has a role in facilitating projects studying PD. Parkinson's UK is a major funder of PD research in addition to providing education and support for patients and carers. Success in developing disease-modifying treatments will require the following: a better understanding of the mechanisms that underlie neuronal cell toxicity and death; the development of animal models that accurately reflect disease progression and which may be used for drug discovery programmes; and the validation of biomarkers which not only permit earlier diagnosis, but also measure disease progression and response to disease-modifying therapy. Such biomarkers are likely to be drawn from a multimodal panel of neuroimaging, blood and cerebrospinal fluid markers.
Advance care planning and palliative care
The relentless progression of most neurodegenerative movement disorders, high symptom burden and paucity of disease-modifying treatments make the requirement for a palliative approach essential. The legal framework for advance care planning (ACP) was provided by the Mental Capacity Act 2005 [67] and discussions regarding ACP can be tailored to the patient and their family with regard to their disease type and stage. Common issues include preferred place of care, antibiotic use for pulmonary infections and the use or withdrawal of artificial nutrition. Palliative care physicians are increasingly involved in the care of patients with advanced PD and other neurodegenerative diseases; unfortunately those with advanced PD are currently more likely to die in hospital than in a hospice or at home.
Conclusion
Tremendous advances have been made in the characterisation of the clinical features and underlying cellular mechanisms that underpin the movement disorders seen in older people. These advances have yet to translate into diseasemodifying therapies, which will revolutionise the care these patients and are currently the focus of intense research efforts.
